logo-loader
RNS
viewANGLE PLC

Notice of AGM

/**/ sup{font-size:80%}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: purple } .x{size:595.3pt 841.9pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.x{}table.bc{width:487.35pt;margin-left:-5.4pt;border-collapse:collapse}td.ay{width:221.4pt;padding:0cm 5.4pt 0cm 5.4pt}p.bd{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold}span.ba{font-size:11.0pt;font-family:"Tahoma","sans-serif"}td.aw{width:244.35pt;padding:0cm 5.4pt 0cm 5.4pt}p.be{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: right}p.bf{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center}p.f,li.f,div.f{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;} p.bg{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align: center}p.bh{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify}span.as{font-size:11.0pt; font-family:"Tahoma","sans-serif"}span.aq{font-size:9.0pt;font-family:"Tahoma","sans-serif"}p.bi{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; page-break-after: avoid}span.ap{font-size: 9.0pt;font-family:"Tahoma","sans-serif"}p.bj{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;margin-right:-34.6pt;text-align:justify;page-break-after: avoid}table.bk{width:470.5pt;margin-left:-10.8pt;border-collapse:collapse}td.al{width:271.05pt;padding:0cm 5.4pt 0cm 5.4pt}p.bl{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;margin-right:-34.6pt;text-align:justify} td.aj{width:177.85pt;padding:0cm 5.4pt 0cm 5.4pt}p.bm{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;margin-right:-34.6pt;text-align:justify; text-indent:13.15pt}span.ai{font-size:9.0pt;font-family:"Tahoma","sans-serif";font-weight:normal}p.bn{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";margin-right:-34.6pt;text-align:justify}p.bo{margin:0cm;margin-bottom:.0001pt;text-align:center;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;margin-right:-34.7pt;text-align:justify}p.bp{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-right: -34.6pt; text-align: justify; text-indent: 13.15pt}span.ae{font-size:9.0pt; font-family:"Tahoma","sans-serif"}p.bq{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify}span.ad{font-size:9.0pt}span.br{color:blue;text-decoration:underline;font-size:9.0pt;font-family:"Tahoma","sans-serif"} p.bs{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; text-align: justify; text-autospace: none}span.ab{font-size:9.0pt;font-family:"Tahoma","sans-serif";color:black}span.z{font-size:9.0pt; font-family:"Tahoma","sans-serif";color:black}p.bt{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify;} /**/
RNS Number : 0123P
Angle PLC
08 October 2019
 

For immediate release

8 October 2019

 

ANGLE plc ("the Company")

 

Notice of AGM and Posting of Annual Report and Accounts

 

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that its  AGM will be held at 2:00 pm on Wednesday 30 October 2019 at ANGLE plc, 10 Nugent Road, Surrey Research Park, Guildford, GU2 7AF. 

 

The Annual Report and Accounts for the year ended 30 April 2019, were posted to shareholders on 7 October 2019, together with the Notice of the Company's Annual General Meeting ("AGM") and are available for download on the Company's website, www.angleplc.com.

 

 

 

For further information ANGLE:

 

ANGLE plc

+44 (0) 1483 343434

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 


finnCap Ltd (NOMAD and Joint Broker)

Corporate Finance - Carl Holmes, Simon Hicks, Max Bullen-Smith

ECM - Alice Lane, Sunila de Silva

 

+44 (0)20 7220 0500

WG Partners (Joint Broker)

Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee

 

+44 (0) 203 705 9330

 

 

FTI Consulting

Simon Conway, Ciara Martin

Matthew Ventimiglia (US)

 

+44 (0) 203 727 1000

+1 (212) 850 5624

 

 

For Frequently Used Terms, please see the Company's website on http://www.angleplc.com/the-parsortix-system/glossary/

 

 

Notes for editors

 

About ANGLE plc www.angleplc.com 

ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include an epitope-independent circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.

 

ANGLE's cell separation technology is called the Parsortix® system, and it enables a liquid biopsy (a simple blood test) to be used to provide the cells of interest to the user in a format suitable for multiple downstream subsequent analyses.  CTCs enable the complete picture of a cancer to be seen as they allow DNA, RNA and protein analysis and the live cells harvested can be cultured.  The Parsortix technology is the subject of 24 granted patents in Europe, the United States, China, Australia, Canada, India, Japan and Mexico with three extensive families of patents are being progressed worldwide.  The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility.  The Parsortix system has a CE Mark in Europe for the indicated use and FDA clearance is in process for the United States with a 400 subject study in metastatic breast cancer. ANGLE is seeking to be the first ever FDA cleared CTC harvesting system and only the third ever FDA cleared liquid biopsy test.  ANGLE has already undertaken two separate 200 subject clinical studies under a program designed to develop an ovarian cancer pelvic mass triage test, with the results showing best in class accuracy (ROC-AUC) of 95.1%.  The pelvic mass triage assay has undergone further refinement and optimisation, and is currently in the process of a 200 patient clinical verification study.

 

ANGLE's technology for the multiplex evaluation of proteins and nucleic acids of all types is called the HyCEADTM Ziplex® platform and is based on a patented flow through array technology.  It provides for low cost, highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry approach (the HyCEAD method) allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. The HyCEAD Ziplex system is ideal for measuring gene expression and other markers directly from Parsortix harvests and was used in the ovarian cancer pelvic mass triage test to achieve best in class accuracy (ROC-AUC) of 95.1%.

 

ANGLE's proprietary technologies can be combined to provide automated, sample-to-answer results in both centralised laboratory and point-of-use cartridge formats.

 

ANGLE has established formal collaborations with world-class cancer centres and major corporates such as Abbott, Philips and QIAGEN, and works closely with leading CTC translational research customers.  These Key Opinion Leaders (KOLs) are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies.  The body of evidence as to the benefits of the Parsortix system is growing rapidly from our own clinical studies in metastatic breast cancer and ovarian cancer and also from KOLs with 25 peer-reviewed publications and numerous publicly available posters, available on our website.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NOACKODBDBDDQKK

Quick facts: ANGLE PLC

Price: 61.8

Market: AIM
Market Cap: £106.76 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ANGLE PLC's Andrew Newland on 'breakthrough in culturing CTCs'

Andrew Newland, chief executive of ANGLE PLC (LON:AGL), tells Proactive's Andrew Scott that researchers using their Parsortix device for capturing circulating tumour cells may have found another “clear high value application” for the system. Not only have they discovered a method of...

on 19/4/18